Key result
The ESCAPE pathway was developed to increase implantable cardioverter defibrillator referrals for patients with low ejection fraction, though no quantitative results are reported in this abstract.
Why the study?
Does the ESCAPE pathway increase the number of patients with low ejection fraction referred for ICD therapy?
Does the ESCAPE pathway increase the number of patients with low ejection fraction referred for ICD therapy?
Answers are grounded in this paper and cite their sources.
The ESCAPE pathway aims to bridge the gap between guidelines and clinical practice by initiating sudden cardiac death risk screening and ICD referral directly at imaging laboratories.
Sudden cardiac death is one of the leading causes of death in the United States, accounting for an estimate 350,000 deaths each year. The US Congress passed a resolution in late September 2008 designating October as "National Sudden Cardiac Arrest Awareness Month." In an effort to raise awareness for preventing unnecessary deaths because of sudden cardiac death, the resolution "calls upon the people of the United States to observe this month with appropriate programs and activities." The response from our institute was to develop a novel pathway named ESCAPE-which is an evidence-based novel pathway for low Ejection fraction and Sudden Cardiac death Awareness and Prevention Eligibility. The main objective of this program is to demonstrate that implementing a simple novel pathway for primary prevention of sudden cardiac arrest leads to an increase in the number of patients with low ejection fraction (<or=35%) referred for implantable cardioverter defibrillators therapy. The key difference of our pathway compared with prior reported algorithms is that it is initiated at imaging laboratories. The registry will consist of consecutive patients presenting to our imaging laboratories (the echocardiography, the nuclear, and the cardiac catheterization laboratories). The ESCAPE pathway defines patients' management based upon 3 key parameters: left ventricular ejection function, heart failure functional class, and an evidence of a prior myocardial infarction or coronary artery disease. We hope that this new novel pathway will help to bridge the gap between the complex guidelines and the actual clinical practice and will help to save many lives.
No takes yet. Share an insight, caveat, or question.
Herzog et al. (2009) studied Sudden cardiac death. ESCAPE pathway was evaluated on Number of patients with low ejection fraction (≤35%) referred for implantable cardioverter defibrillators therapy. The ESCAPE pathway was developed to increase implantable cardioverter defibrillator referrals for patients with low ejection fraction, though no quantitative results are reported in this abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: